Metastatic Medullary Thyroid Cancer Clinical Trial
Official title:
CAPRELSA® REGISTRY: a Belgian Registry to Evaluate the Use of Vandetanib (Caprelsa®) in Current Clinical Practice
In this registry it is planned to include all Belgian patients diagnosed with aggressive and
symptomatic unresectable locally advanced or metastatic Medullary Thyroid Cancer (MTC) who
have been prescribed Caprelsa® (vandetanib).
The characteristics of patients receiving Caprelsa® (vandetanib) will be described.
Therefore real life data regarding demographic characteristics, evolution of the disease,
RET mutation status, the treatment before, during and after vandetanib, dose and duration of
treatment with Caprelsa® (vandetanib) and time of progression or death (if applicable) will
be included.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Suspended |
NCT01927887 -
Pre-Operative Nodal Staging of Thyroid Cancer Using Ultra-Small Superparamagnetic Iron Oxide Magnetic Resonance Imaging (USPIO MRI): Preliminary Study
|
N/A | |
| Completed |
NCT00654238 -
Phase II Trial of Sorafenib (Nexavar) in Patients With Advanced Thyroid Cancer
|
Phase 2 | |
| Recruiting |
NCT04877613 -
GFRα4 CAR T Cells in MTC Patients
|
Phase 1 |